Publications by authors named "Candice Junge"

Claim this Profile
A
ATXN7-Related Cone-Rod Dystrophy: The Integrated Functional Evaluation of the Cerebellum (CERMOI) Study.
Marco Nassisi, Giulia Coarelli, Benoit Blanchard, Charlotte Dubec-Fleury, Karima Drine, Candice Junge

JAMA Ophthalmol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers.
Roger M Lane, Taher Darreh-Shori, Candice Junge, Dan Li, Qingqing Yang

BMC Neurol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Tau-targeting antisense oligonucleotide MAPT in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
Catherine J Mummery, Anne Börjesson-Hanson, Daniel J Blackburn, Everard G B Vijverberg, Peter Paul De Deyn, Candice Junge

Nat Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease: A Randomized Clinical Trial.
Amanda L Edwards, Jessica A Collins, Candice Junge, Holly Kordasiewicz, Laurence Mignon

JAMA Neurol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tau-targeting antisense oligonucleotide MAPT in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
Catherine J Mummery, Anne Börjesson-Hanson, Daniel J Blackburn, Everard G B Vijverberg, Peter Paul De Deyn, Candice Junge

Nat Med· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pelizaeus-Merzbacher Disease: A Caregiver Assessment of Disease Impact.
Katrina M Moore, Nicole I Wolf, Grace Hobson, Kristina Bowyer, Jordan McSherry, Candice Junge

J Child Neurol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autologous CD34 Cell Therapy for Refractory Angina: 2-Year Outcomes From the ACT34-CMI Study.
Timothy D Henry, Gary L Schaer, Jay H Traverse, Thomas J Povsic, Charles Davidson, Candice Junge

Cell Transplant· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PreSERVE-AMI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intracoronary Administration of Autologous CD34+ Cells in Patients With Left Ventricular Dysfunction Post STEMI.
Arshed A Quyyumi, Alejandro Vasquez, Dean J Kereiakes, Marc Klapholz, Gary L Schaer, Candice Junge

Circ Res· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The RENEW Trial: Efficacy and Safety of Intramyocardial Autologous CD34(+) Cell Administration in Patients With Refractory Angina.
Thomas J Povsic, Timothy D Henry, Jay H Traverse, F David Fortuin, Gary L Schaer, Candice Junge

JACC Cardiovasc Interv· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study.
Thomas J Povsic, Candice Junge, Adel Nada, Richard A Schatz, Robert A Harrington

Am Heart J· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia.
Douglas W Losordo, Melina R Kibbe, Farrell Mendelsohn, William Marston, Vickie R Driver, Candice E Junge

Circ Cardiovasc Interv· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and clinical significance of cardiac biomarker elevation during stem cell mobilization, apheresis, and intramyocardial delivery: an analysis from ACT34-CMI.
Thomas J Povsic, Douglas W Losordo, Kenneth Story, Candice E Junge, Richard A Schatz

Am Heart J· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activation of protease activated receptor 1 increases the excitability of the dentate granule neurons of hippocampus.
Kyung-Seok Han, Guido Mannaioni, Cecily E Hamill, Jaekwang Lee, Candice E Junge

Mol Brain· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The serine protease plasmin cleaves the amino-terminal domain of the NR2A subunit to relieve zinc inhibition of the N-methyl-D-aspartate receptors.
Hongjie Yuan, Katie M Vance, Candice E Junge, Matthew T Geballe, James P Snyder

J Biol Chem· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasmin potentiates synaptic N-methyl-D-aspartate receptor function in hippocampal neurons through activation of protease-activated receptor-1.
Guido Mannaioni, Anna G Orr, Cecily E Hamill, Hongjie Yuan, Katherine H Pedone, Candice E Junge

J Biol Chem· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protease-activated receptor-1 in human brain: localization and functional expression in astrocytes.
Candice E Junge, C Justin Lee, Katherine B Hubbard, Zhoabin Zhang, Jeffrey J Olson

Exp Neurol· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia.
Candice E Junge, Taku Sugawara, Guido Mannaioni, Sudar Alagarsamy, P Jeffrey Conn

Proc Natl Acad Sci U S A· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis